TickerFacts.

TG Therapeutics, Inc. (TGTX): Cost of Revenue

Annual figures by period end, from SEC filings.

$100.71M
Year ended 2025-12-31
$140.94M
Trailing 12 months to 2026-06-30
n/m
3-year compound annual growth
2021-12-31: $790.0K2022-12-31: $265.0K2023-12-31: $14.13M2024-12-31: $38.49M2025-12-31: $100.71M$100.71M
2021-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$100.71M+161.7%2026-02-27, From 2025-01-01
2024-12-31$38.49M+172.4%2026-02-27, From 2024-01-01
2023-12-31$14.13Mn/m2026-02-27, From 2023-01-01
2022-12-31$265.0K-66.5%2025-03-03, From 2022-01-01
2021-12-31$790.0Kn/a2024-02-29, From 2021-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
TG Therapeutics, Inc. (TGTX)2025-12-31$100.71M+161.7%
Opko Health, Inc. (OPK)2025-12-31$400.94M-18.9%
Insmed Inc (INSM)2025-12-31$122.94M+43.4%
Organogenesis Holdings Inc. (ORGO)2024-12-31$115.74M+8.7%
Kiniksa Pharmaceuticals International, plc (KNSA)2025-12-31$77.67M+27.5%
HUTCHMED (China) Ltd (HCM)2025-12-31$336.35M-3.6%
Supernus Pharmaceuticals, Inc. (SUPN)2025-12-31$74.56M-4.3%
Amphastar Pharmaceuticals, Inc. (AMPH)2025-12-31$363.83M+1.6%
Pacira BioSciences, Inc. (PCRX)2025-12-31$149.75M-12.1%

Compare TGTX, OPK, INSM, ORGO side by side · Screen every company in Pharmaceutical Preparations ↗